FRIENDSWOOD, Texas, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at Baird’s 2025 Global Healthcare Conference on Wednesday, Sept. 10, 2025, at 10:15 a.m. Eastern time.
A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at ir.castlebiosciences.com/events-presentations/. A replay of the webcast will be available following the conclusion of the live broadcast.
Castle will also be available for one-on-one investor meetings during the Wells Fargo 20th Annual Healthcare Conference on Sept. 4, 2025, and the 9th Annual Lake Street Best Ideas Growth (BIG9) Conference on Sept. 11, 2025. Meetings may be requested exclusively through Wells Fargo and Lake Street Capital Markets.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
Investor Contact:
Camilla Zuckero
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Allison Marshall
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$37.88 |
| Daily Change: | 2.16 6.05 |
| Daily Volume: | 594,683 |
| Market Cap: | US$1.110B |
November 14, 2025 November 11, 2025 November 03, 2025 November 03, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
